felbamate has been researched along with Abdominal Epilepsy in 31 studies
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.
felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Felbamate (FBM, Felbatol/Taloxa), a new antiepileptic drug (AED), was tested in a placebo-controlled add-on design in 73 patients with therapy refractory Lennox-Gastaut syndrome." | 9.07 | Felbamate in the treatment of Lennox-Gastaut syndrome. ( Jensen, PK, 1994) |
| "felbamate appears to be an effective new AED: the most adverse effects occurring during administration of FBM are mild to moderate gastrointestinal (nausea, vomiting and anorexia) and central nervous system (headache, sonnolence, diplopia, dizziness and insomnia) disturbances." | 6.68 | [Felbamate: a long-term study in subjects with refractory epilepsy]. ( De Romanis, F; Sopranzi, N, 1997) |
| "Felbamate (FBM) is an effective and safe novel antiepileptic drug (AED) for add-on treatment in adults with refractory partial seizures as shown in three pivotal controlled trials." | 6.38 | Felbamate: successful development of a new compound for the treatment of epilepsy. ( Schmidt, D, 1993) |
| "Felbamate has been approved for refractory partial seizures since the early nineties." | 5.42 | The rise and fall of felbamate as a treatment for partial epilepsy--aplastic anemia and hepatic failure to blame? ( Billa, G; Chudasama, H; Goswami, S; Rane, J; Shah, R; Thakkar, K, 2015) |
| "Felbamate (FBM, Felbatol/Taloxa), a new antiepileptic drug (AED), was tested in a placebo-controlled add-on design in 73 patients with therapy refractory Lennox-Gastaut syndrome." | 5.07 | Felbamate in the treatment of Lennox-Gastaut syndrome. ( Jensen, PK, 1994) |
| "Felbamate is a second-generation antiepileptic drug that can be used as add-on therapy to standard antiepileptic drugs." | 2.82 | Felbamate add-on therapy for drug-resistant focal epilepsy. ( Bresnahan, R; Dong, J; Geng, J; Martin-McGill, KJ; Ni, H; Shi, LL, 2022) |
| "felbamate appears to be an effective new AED: the most adverse effects occurring during administration of FBM are mild to moderate gastrointestinal (nausea, vomiting and anorexia) and central nervous system (headache, sonnolence, diplopia, dizziness and insomnia) disturbances." | 2.68 | [Felbamate: a long-term study in subjects with refractory epilepsy]. ( De Romanis, F; Sopranzi, N, 1997) |
| "Felbamate (FBM) is a new antiepileptic drug (AED) that has been tested in open and controlled studies in patients with therapy-refractory partial-onset seizures." | 2.67 | Felbamate in the treatment of refractory partial-onset seizures. ( Jensen, PK, 1993) |
| "Felbamate was statistically superior to placebo in seizure reduction, percent seizure reduction, and truncated percent seizure reduction." | 2.67 | Felbamate for partial seizures: results of a controlled clinical trial. ( Bertram, E; Cereghino, JJ; Dreifuss, FE; Drury, I; Graves, NM; Jacobs, MP; Leppik, IE; Pledger, GW; Santilli, N; Tsay, JY, 1991) |
| " Another reason why the efficacy of FBM cannot yet be fully assessed is that in all the studies the FBM dosage was limited to a maximum of 3,600 mg/day or 45 mg/kg/day." | 2.39 | Felbamate in the treatment of partial-onset seizures. ( Bourgeois, BF, 1994) |
| " GBP is also active in this population, but only the 1,800 mg/day dosage was significantly better than placebo with respect to percent responders." | 2.39 | Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs. ( French, JA, 1996) |
| "Felbamate (FBM) is an effective and safe novel antiepileptic drug (AED) for add-on treatment in adults with refractory partial seizures as shown in three pivotal controlled trials." | 2.38 | Felbamate: successful development of a new compound for the treatment of epilepsy. ( Schmidt, D, 1993) |
| "Felbamate has been approved for refractory partial seizures since the early nineties." | 1.42 | The rise and fall of felbamate as a treatment for partial epilepsy--aplastic anemia and hepatic failure to blame? ( Billa, G; Chudasama, H; Goswami, S; Rane, J; Shah, R; Thakkar, K, 2015) |
| "Anorexia and insomnia were reported in 20% and 16% of the patients, respectively." | 1.29 | Efficacy of felbamate in therapy for partial epilepsy in children. ( Anderson, J; Carmant, L; Holmes, GL; Mikati, MA; Rifai, N; Sawyer, S, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (70.97) | 18.2507 |
| 2000's | 4 (12.90) | 29.6817 |
| 2010's | 4 (12.90) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, LL | 4 |
| Bresnahan, R | 1 |
| Martin-McGill, KJ | 1 |
| Dong, J | 4 |
| Ni, H | 4 |
| Geng, J | 4 |
| Wu, T | 3 |
| Thakkar, K | 1 |
| Billa, G | 1 |
| Rane, J | 1 |
| Chudasama, H | 1 |
| Goswami, S | 1 |
| Shah, R | 1 |
| Héberlé, C | 1 |
| Berquin, P | 1 |
| Larnicol, N | 1 |
| Wallois, F | 1 |
| Brodie, MJ | 1 |
| Pellock, JM | 1 |
| Devinsky, O | 2 |
| Faught, RE | 1 |
| Wilder, BJ | 1 |
| Kanner, AM | 1 |
| Kamin, M | 2 |
| Kramer, LD | 3 |
| Rosenberg, A | 3 |
| Vazquez, B | 1 |
| Luciano, D | 1 |
| Luer, MS | 1 |
| Jensen, PK | 2 |
| Bourgeois, BF | 1 |
| Carmant, L | 1 |
| Holmes, GL | 1 |
| Sawyer, S | 1 |
| Rifai, N | 1 |
| Anderson, J | 1 |
| Mikati, MA | 1 |
| Graves, NM | 2 |
| Schmidt, D | 1 |
| Faught, E | 1 |
| Sachdeo, RC | 1 |
| Remler, MP | 1 |
| Chayasirisobhon, S | 1 |
| Iragui-Madoz, VJ | 1 |
| Ramsay, RE | 1 |
| Sutula, TP | 1 |
| Kanner, A | 1 |
| Harner, RN | 1 |
| Kuzniecky, R | 1 |
| Bourgeois, B | 1 |
| Leppik, IE | 3 |
| Sackellares, JC | 1 |
| Laxer, K | 1 |
| Lesser, R | 1 |
| Messenheimer, JA | 1 |
| Wilner, AN | 1 |
| French, JA | 2 |
| De Romanis, F | 1 |
| Sopranzi, N | 1 |
| Elger, CE | 1 |
| Bauer, J | 1 |
| Scherrmann, J | 1 |
| Widman, G | 1 |
| Canger, R | 1 |
| Vignoli, A | 1 |
| Bonardi, R | 1 |
| Guidolin, L | 1 |
| White, HS | 1 |
| Contin, M | 1 |
| Riva, R | 1 |
| Albani, F | 1 |
| Baruzzi, AA | 1 |
| Ebert, U | 1 |
| Reissmüller, E | 1 |
| Löscher, W | 1 |
| Kmieć, T | 1 |
| Jóźwiak, S | 1 |
| Kuczyński, D | 1 |
| Karkowska, B | 1 |
| Bachański, M | 1 |
| Sachdeo, R | 1 |
| Sachdeo, S | 1 |
| Dreifuss, FE | 1 |
| Pledger, GW | 1 |
| Santilli, N | 1 |
| Drury, I | 1 |
| Tsay, JY | 1 |
| Jacobs, MP | 1 |
| Bertram, E | 1 |
| Cereghino, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
13 reviews available for felbamate and Abdominal Epilepsy
| Article | Year |
|---|---|
Felbamate add-on therapy for drug-resistant focal epilepsy.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Drug Therapy, Combination; Drug-Related Side Effects and A | 2022 |
Felbamate as an add-on therapy for refractory partial epilepsy.
Topics: Anticonvulsants; Drug Resistance; Epilepsies, Partial; Felbamate; Humans; Phenylcarbamates; Propylen | 2017 |
Felbamate as an add-on therapy for refractory epilepsy.
Topics: Anticonvulsants; Epilepsies, Partial; Felbamate; Humans; Phenylcarbamates; Propylene Glycols; Random | 2014 |
Felbamate as an add-on therapy for refractory epilepsy.
Topics: Anticonvulsants; Epilepsies, Partial; Felbamate; Humans; Phenylcarbamates; Propylene Glycols; Random | 2011 |
New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Approval; Epileps | 1994 |
Felbamate in the treatment of partial-onset seizures.
Topics: Adult; Anticonvulsants; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Met | 1994 |
Felbamate.
Topics: Adult; Anticonvulsants; Child; Child, Preschool; Clinical Trials as Topic; Drug Interactions; Epilep | 1993 |
Felbamate: successful development of a new compound for the treatment of epilepsy.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, | 1993 |
Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyc | 1996 |
Aggravation of focal epileptic seizures by antiepileptic drugs.
Topics: Acetates; Acute Disease; Adult; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 1998 |
Role of new and established antiepileptic drugs.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Drug Interactions; Epilepsies, Partial; Epilepsy | 1998 |
Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Epilepsies, Partial; Felbamate; Fru | 1999 |
The role of new antiepileptic drugs.
Topics: Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epilepsies, Partial; Epilepsy; Epi | 2001 |
12 trials available for felbamate and Abdominal Epilepsy
| Article | Year |
|---|---|
Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures.
Topics: Adult; Aged; Anticonvulsants; Double-Blind Method; Epilepsies, Partial; Evaluation Studies as Topic; | 1995 |
Felbamate in the treatment of Lennox-Gastaut syndrome.
Topics: Adult; Anticonvulsants; Child; Drugs, Investigational; Epilepsies, Partial; Epilepsy; Felbamate; Fol | 1994 |
Felbamate in the treatment of refractory partial-onset seizures.
Topics: Adult; Anticonvulsants; Child; Double-Blind Method; Drug Therapy, Combination; Epilepsies, Partial; | 1993 |
Felbamate monotherapy for partial-onset seizures: an active-control trial.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Anticonvulsants; Aspartate Aminotransferases; Double- | 1993 |
Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures.
Topics: Adolescent; Adult; Anticonvulsants; Double-Blind Method; Epilepsies, Partial; Felbamate; Female; Hum | 1993 |
Efficacy of felbamate monotherapy.
Topics: Anticonvulsants; Epilepsies, Partial; Felbamate; Humans; Phenylcarbamates; Propylene Glycols; Resear | 1993 |
[Felbamate: a long-term study in subjects with refractory epilepsy].
Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsies, Partial; Epilepsy; | 1997 |
Felbamate in refractory partial epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Drug Resistance; Drug Therapy, Combination; Epileps | 1999 |
Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Chil | 1999 |
[Gabitril as an additive drug in therapy of intractable epileptic seizures in children].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clonazepam; Drug Therapy, Combi | 2000 |
Felbamate monotherapy: controlled trial in patients with partial onset seizures.
Topics: Adolescent; Adult; Anticonvulsants; Double-Blind Method; Epilepsies, Partial; Felbamate; Female; Hum | 1992 |
Felbamate for partial seizures: results of a controlled clinical trial.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Epilepsies, P | 1991 |
6 other studies available for felbamate and Abdominal Epilepsy
| Article | Year |
|---|---|
The rise and fall of felbamate as a treatment for partial epilepsy--aplastic anemia and hepatic failure to blame?
Topics: Anemia, Aplastic; Anticonvulsants; Drug Resistant Epilepsy; Epilepsies, Partial; Felbamate; Humans; | 2015 |
Vagus nerve stimulation in a case of epilepsy with CSWSS: respiratory side effects during sleep.
Topics: Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Clobazam; Combined Modali | 2002 |
Taming the brain storms: felbamate updated.
Topics: Anemia, Aplastic; Anticonvulsants; Chemical and Drug Induced Liver Injury; Drug Approval; Drug Monit | 1995 |
Criteria for use of felbamate in adult, adolescent, and child inpatients and outpatients.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsies, Parti | 1994 |
Efficacy of felbamate in therapy for partial epilepsy in children.
Topics: Adolescent; Age Factors; Anorexia; Anticonvulsants; Child; Child, Preschool; Drug Combinations; Drug | 1994 |
The new antiepileptic drugs lamotrigine and felbamate are effective in phenytoin-resistant kindled rats.
Topics: Amygdala; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drug Resistance; Electric Stim | 2000 |